Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Senti Biosciences Announces $8M CIRM Grant To Support Clinical Development Of SENTI-202 CAR-NK Cell Therapy For Hematologic Malignancies; First Tranche Expected In August 2024; Phase 1 Trial Enrolling Patients In US And Australia, Initial Efficacy Data Anticipated By Year-End 2024

Author: Benzinga Newsdesk | August 05, 2024 08:10am

Posted In: SNTI